Martin serves as Delpor’s Chief Science Officer. He is responsible for leading the company’s scientific innovation and managing all R&D activities. Dr. Martin has worked in drug delivery for over 30 years and is the inventor of Delpor’s PROZOR technology. Prior to founding Delpor, he held positions at several pharmaceutical companies including ALZA, Johnson and Johnson, and SEQUUS Pharmaceuticals.As the Chief Science Officer at SEQUUS, Dr. Martin assembled and led the research team which developed long circulating pegylated liposomes (“Stealth Liposomes”). A product derived from this technology is doxorubicin liposome injection (DOXIL). DOXIL is now approved worldwide for the treatment of ovarian and breast carcinoma and generates sales in excess of $800M annually. During his tenure at SEQUUS, Dr. Martin also served as a member of the senior operating management team. His responsibilities included formulation of company-wide research strategy, management of the research unit, and supervision of the Company’s network of extramural investigators (10 academic labs). He also acted as principal technical spokesman with the FDA, Wall Street analysts, key investors, professional organizations, activist groups and commercial partners, and played a key role in setting patent policy and priorities, and in patent prosecution.Following the acquisition of SEQUUS by ALZA, Dr. Martin served as Distinguished Research Fellow at ALZA Corporation, a company devoted to the development of advanced drug delivery systems. While at ALZA he was responsible for the assessment of new drug delivery technologies.Dr. Martin has presented to the FDA on multiple occasions and has developed a good working relationship with the Agency. He is the inventor of 45 issued US patents, and several more in prosecution all related to drug delivery systems. He has also been awarded the prestigious NIH Postdoctoral Fellowship award. Dr. Martin holds a BS in Biology from the University of San Francisco and a PhD in Biochemistry from Northwestern University.